Summary: In a first-in-human phase 1 programme, single ascending subcutaneous doses of the long-acting FGF21 analog zalfermin in healthy overweight or obese men showed dose-proportional pharmacokinetics with a roughly 120-hour half-life supporting weekly dosing, plus improved plasma lipids, with mostly mild-to-moderate gastrointestinal adverse events and no deaths.
PICO Summary
| Element | Detail |
|---|---|
| Population | 98 healthy men with BMI 25.0–34.9 across two studies (56 in the dose-ranging study; a second study of 24 Japanese and 18 non-Asian men for cross-ethnic comparison), followed 36 days. |
| Intervention | Single ascending subcutaneous doses of zalfermin (2, 6, 12, 24, 48, 96, 180 mg); matched doses of 12, 30, 96 mg in the ethnicity study. |
| Comparison | Placebo. |
| Outcome | Dose-proportional Cmax and AUC; Tmax 24–54 h; serum half-life ~120 h (weekly dosing feasible). Significant plasma lipid improvements. Adverse events non-serious, mainly gastrointestinal, mostly mild-moderate, greater at the highest doses; no deaths. |
Expert Commentary
FGF21 is a mechanistically attractive target, distinct from the incretin pathway, working through brown fat, adiponectin, and direct hepatic effects, and the practical achievement here is real: engineering a roughly five-day half-life turns a hormone with a one-to-two-hour native lifespan into a plausible once-weekly drug. So as a phase 1 result this is a clean success on its own terms, with predictable pharmacokinetics, a lipid signal, and acceptable tolerability. My discipline is to keep expectations where the evidence sits, which is very early. This is a single-dose, healthy-volunteer, male-only study with no patients, no weight or glycaemic efficacy, and the sobering backdrop that the FGF21 class has repeatedly looked good early and then disappointed in MASH trials, pegbelfermin being the cautionary example. Can I use this with my patients? Not at all, and I would actively temper any hype: zalfermin is years and several trials away from clinical relevance, and a lipid change in healthy men predicts nothing about hard outcomes. The ethnicity bridging data are a sensible touch for global development. I await multiple-ascending-dose and patient efficacy studies before forming any real view.
References
Dahl K, Friedrichsen MH, Ribel-Madsen R, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel long-acting FGF21 analog zalfermin. Clin Transl Sci. 2025;18(12):e70435. doi:10.1111/cts.70435